Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Smoldering Multiple Myeloma 1

Interventions

pembrolizumab 604 Carboplatin 372 Paclitaxel 282 Cisplatin 267 Gemcitabine 252 Pemetrexed 193 Bevacizumab 190 Docetaxel 185 Nivolumab 181 Injections 167 Cyclophosphamide 147 atezolizumab 138 Fluorouracil 133 Capecitabine 133 Oxaliplatin 132 Dexamethasone 127 Fulvestrant 113 durvalumab 112 130-nm albumin-bound paclitaxel 110 fludarabine 101 Cetuximab 100 Leucovorin 97 Rituximab 94 venetoclax 90 Lenalidomide 83 enzalutamide 77 Prednisone 76 Azacitidine 74 Irinotecan 72 Ipilimumab 72

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × IPH-2101 × 1 year × Clear all

NCT01222286 2026-05-14

KIRMONO

Innate Pharma

Phase 2 Completed

30 enrolled 10 charts

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡